02- Strong Relationships with Leading Global Generic Companies: As of March 31, 2021, 16 of the 20 largest generic companies globally were customers of Glenmark Lifesciences Limited (Source: “A Year of Surprises Shakes Up Off-Patent Industry” | Informa, 2020.
03- Strong Focus on Sustainability in Operations: Various initiatives have been taken up - relating to energy efficiency, recovery and reuse of solvents and water conservation, recovery and reuse to reduce carbon footprint. All the manufacturing facilities currently have zero liquid discharge (“ZLD”) capabilities.
Glenmark Lifesciences is a leading developer and manufacturer of select high value, non-commoditized active pharmaceutical ingredients (“APIs”) in chronic therapeutic areas, including cardiovascular disease, central nervous system diseases, gastro-intestinal disorders etc.
The company is also increasingly providing contract development and manufacturing operations (“CDMO”) services to a range of multinational pharmaceutical and specialty pharmaceutical companies. Glenmark Lifesciences is a research and development (“R&D”) driven API manufacturer, focused on undertaking dedicated R&D in existing products and also in areas where there a strong belief of growth potential in the future.
Glenmark Lifesciences is currently a wholly-owned subsidiary of its Promoter, Glenmark Pharmaceuticals Limited (“Glenmark”), a research-oriented, global pharmaceutical company, which was established in 1977 and is listed on the BSE and NSE.
In 2019, the API manufacturing business of Glenmark Pharmaceuticals was sold and spun off into Glenmark Lifesciences as part of a broader reorganization designed to place Glenmark on an accelerated trajectory to attain its objectives in three different verticals. Following the Spin-off, Glenmark Lifesciences operates as an independent, professionally-managed global API business.
As of March 31, 2021, the company had a portfolio of 120 molecules globally and sold APIs in India and exported to multiple countries in Europe, North America, Latin America, Japan and the rest of the world
Your email address will not be published.
